Canada Markets open in 2 hrs 28 mins

PLx Pharma Inc. (PLXP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8700-0.1000 (-3.37%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.9700
Open2.9900
Bid1.5000 x 1300
Ask4.4800 x 900
Day's Range2.7900 - 3.0200
52 Week Range1.9250 - 21.5000
Volume120,175
Avg. Volume246,944
Market Cap79.031M
Beta (5Y Monthly)4.44
PE Ratio (TTM)N/A
EPS (TTM)-3.1020
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
  • GlobeNewswire

    PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

    VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac EventsSPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury

  • Zacks

    PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

    PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

    BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) Cash & Cash Equivalent Balance of $52.5 Million as of March 31, 2022Disciplined Spending to Support Strategic Growth SPARTA, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “C